Reports of burst balloons prompt Canadian recall of Sapien 3 Ultra

Reports of burst balloons with the Sapien 3 Ultra heart valve have resulted in an urgent safety notice from the manufacturer and a Canadian recall of the system.

The announcement comes just eight months after the Sapien 3 Ultra, distributed by Edwards Lifesciences, was granted a CE mark in the European Union and seven months after the valve gained FDA approval in the U.S. At the time, the system was indicated for use in high-risk transcatheter aortic valve replacement (TAVR) patients with severe, symptomatic aortic stenosis.

In an urgent field safety notice issued this month, Edwards addressed physicians, disclosing the company had received a handful of reports of burst balloons. The overall observed complaint rate for the bursts was around 1%, the notice read, “based on the limited experience with the device of which approximately 0.5% had clinical implications for the patient such as difficulty removing the delivery system, vascular injury, bleeding and/or need for surgical intervention.”

A burst balloon can result in significant difficulty retrieving the Sapien 3 system into the sheath and withdrawing it from the patient, the company said.

On July 16 the Canadian government took Edwards’ warning to heart, issuing a recall of the product in Canada. The brief described the recall as a type 1 hazard.

Edwards said it’s in the process of updating the Sapien 3 Ultra system’s training materials to include recommendations for what to do in the case of a burst balloon. The company said excess inflation volume and fast inflation were the main two culprits behind reported cases so far.

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."